a challenging results. and families you and our safe everyone your healthy Thank we join for today taking update you, thanks are during the discuss and provide to welcome quarter us and We these and first afternoon time times. as XXXX hope Peter. Good business
pandemic. light quarters second global personal the unexpected on in business of first remembered The times by of interruptions XXXX this brought very and be trying as will and
Covid-XX how were rest that the In along the world country to the the of matter, responded and decisively with I operational this of disruption thrust has adapted waters. am to Matinas agile I we, to seriousness rest our have research quickly employees, into the proud minimize our participants of and challenges. team crisis, very well-being structure, of say early and recognizing acting the of address the prioritize to we early March Thanks uncharted any study and for the incredibly to partners. and
Prevention the first the guidance continuity. the implemented business the implemented we variety state strategies reduce employees with of In all business quarter, home mitigation to US New During from a risk Jersey, travel. from suspended of as and and as line well for Control and we Center of Disease all ensure measures work
We and ensure development programs the also development and safety implemented continuing of to the research our of emphasize all to our while advancement team partners. processes of
Our our the facility. the prioritized lab pandemic From employees of safety sites have Bridgewater interest to And a activities throughout all hospitals clinical lab in efficiency. Covid-XX challenge study and perspective, certain we clinical returned for an world. ongoing is the recently and manufacturing and
made we first temporarily correct late the enrollment key As you each our to trials. quarter, in know, in the pause of decision clinical
place. in have of the with as that was time safety while trials the been trial and have country clinically to in resume monitoring with decision working the employees of our investigators assessment our across protocols enrollment and as ensuring site seen the health to we and patients study throughout globe, appropriate clinical important on plans clinical and participants all areas sites improvement and clinical clinical our many closely data. in Since This well-being meaningful gradual of ensure trial taken trials, integrity as the and well we capturing
candidates directly speak of in each stage of in clinical our context more the moments. to this will a I few
the challenges as serve of critical Matinas who at pursuing We sheet to these to ever of highlight committed balance will serving position points diseases. dealing our meaningful those quarters. our posed of us as mission anticipated a remain needs with patients as are believe this care to For the by serious health as the several providers strength the mission and patients Covid-XX for we from of We over inflection the enable care stay with them. solid us course coming well
generation remains the trial, therapy. versus study important Vascepa for crossover our enhanced Our compelling an MATXXXX comparative next of study prescription-only and head-to-head omega-X
thankful necessary to Dr. Director each safety able with implementing all Kevin the is Study eight subjects and to for procedures trial expected be as reasonable from announce ENHANCE-IT to and our well study monitors. today as our that locations clinical for we Maki, And in are closely teams We resume working enrollment June. of are
data be this ENHANCE-IT depending of June, sooner on is that Covid-XX. quarter some fourth With the could enrollment. we revision are guidance line believe revising We it certainly circumstances for first in guidance under line to appropriate the in modestly XXXX data resume our expected top while the slight remains top of quarter around of uncertainties available delivery XXXX, from possible given the that of to the
remain we end our this of in for FDA with year. quarter of on track phase Importantly, third meeting the the
both studies focus human preparing in our our comparative planned will pharmacokinetic X. MATXXXX with do supply as final in phase well job protocol our the study to of are package prepare the as We severe meeting the disruption from an to briefing on MATXXXX The of stages our continued while for X taking for for request has maintaining the steps trials hypertriglyceridemia. which without our excellent chain results and team clinical toxicology patients of phase actively and
MATXXXX and believe EPA meals. class administration than in X taken levels, such to potential clear having has dosing on to to the as prescription more day that with and omega once in differentiation without pharmacokinetics, markers be continue PCSKX best-in-class of the convenience We lipid and impact split a need with to triglycerides
generally to MATXXXX, our or and this ENHANCE-IT candidate talking this applying as moment about before I however, drug to specifics resuming infectious spend results lipid impact delivery our area. to turn on I reporting technology, the a would to soon the as LNC forward trial look nanocrystal get now We and pandemic lead disease from like I of platform the global like into would possible.
spotlight. attention health society unintended Dealing and Covid-XX the to prevention hidden interesting is of thrust threats enemies disease. economic being the has these feature into An infectious potential with given increased pose treatment they and and the of been the to and
Emerging We with care many are infections may including also as intensive one-third unfortunately Covid-XX requiring that suggest of on had fungal emergence infections. Covid-XX battling that deadly infections invasive has be fungal impact phase of the the seeing reports as infections. patients severe life-threatening of other in
and Pharmacoeconomics. potentially for of manner direct become complex of not is a In time. allowing administration seeing as of believe ensuring to a the importance that enough development new addition, molecules of the can is delivery body options that our only We the effectiveness we therapy require variety amphotericin which well delivery a in solution amikacin at of oral for and are targeted outpatient get improved drug stage the the LNC positioned right critical and treatment also like platform element convenience afflicted but to a drugs with for of a B center repurposed area in takes
the B, oral and and for potential we of drug gold In infections of treatment the preclinical invasive on mucosal the deadly LNC fungal we treatment studies Building have infections. prevention fungal believe the impressive data of two perhaps phase fungal of the extensive treatment two infections. in invasive standard and in and drug broad MATXXXX, our choice of amphotericin conducted formulation the antifungal spectrum ultimately potent
treatment investigate fungal meningitis deadly system. to infection the positioned face and MATXXXX is a of central currently the cryptococcal of nervous of
which supported was of the suspended National Institutes by previously have EnACT at financially of temporarily we March, announced our mandate is end by As Drug the Authority. of Health the of National Uganda trial MATXXXX
announced in The clinical key this that available Today possible. patients significant anticipate as need in a unmet from based is suffering as we the on in cryptococcal EnACT resuming latest meningitis trial HIV factor enrollment June. restarting guidance, soon of medical Uganda we
resume and clinical we of in next Following discussion first Uganda planning patients of treatment the cohort to the enrollment month. in our ten with are site
to the the as patients an Given of second be this patients the to this in announcement cohort timing later position from of year. to we would cohort expect updated progression first to make
cohort value inflection is potential continue an significant believe therapy. point this progression with that We drug population for important and to this in patient this
limited or LPAD have than companies this more XX,XXX area. potential than performed We population drugs believe an pathway In where view a annually peer as course according antifungal MATXXXX. indication more with be approval, important there therapy cryptococcal who meningitis in and pricing valuable for potentially for XXXX alone to the per of of States research cases for eligible could MATXXXX gateway United we market are
approved antibacterial a US, with infection antifungal approved treat the or unmet serious pathway patients or In drug of is LPAD a the a in drug an needs. life-threatening to limited population under
the course, opportunity of Of cryptococcal world greater the meningitis significantly. including is fungal incidence commercial infections around potentially the expanding thereby even invasive
streamlined Following become choice of approval other indications. of to suited treatment fungal the approvals invasive we that many for position is drug XXX-bX and MATXXXX could well meningitis, infections. MATXXXX and cryptococcal for This believe antifungal the
several could drugs available very spectrum the for treating the ability approved which share If invasive treat to first billion MATXXXX of speaks broad fungal with this time great oral would currently the MATXXXX invasive give large physicians dollars potential and an potent utilize for for formulation. market. believe infections amount fungal sales highly drug the to a to antifungal which safely Total capture infections we to most
of clinical In platform to oral with quarter a broad-spectrum MATXXXX technology. LNC we supported acute progress and formulation asset another the chronic made used our commonly aminoglycoside by first amikacin, of also infections. bacterial treat is XXXX, delivery stage our
by drug Foundation which supported positions by for now Fibrosis the potentially preclinical data candidate grant on Important a which MATXXXX this work made Cystic yielded further promising was development.
Foundation through X. preclinical an first a development work small important in commitment grant on the Fibrosis continue quarter to to the dialogue Cystic are in support bridge And product. received ongoing We this with phase
Foundation advance support this the currently our allocated and resources, to Fibrosis drug. rely Given would its upon we Cystic
back year. forward to application given in We of our are on the optimistic discussions to and our this date half second look hearing
that believe has clinical and MATXXXX significant potential. We financial
limited We aware version approval a safety. a program significant allocation box value been which Insmed, very approved to XXXX $X.X LPAD an under create inhaled accompanied of black has of with with cap to but warnings related the by that market keenly able are billion in the was company
tolerated profile where most the events inhale adverse that could be Arikayce MATXXXX believe by to having for caused Insmed's serious are the it far suggests We better of than product.
needed we As patients infections. advance provide the overdue a better pulmonary would MATXXXX forward attention, the look for which much bacterial infectious of prevention much battling to receive disease continues tolerated treatment to and potential and to solution
announced during the of frequently I to the some interruption ongoing. are with these We of projects pharma from am about Covid-XX. we pleased on XXXX. three asked all making announced some are progress that that collaborations with big report remain Albeit we
for collaboration our we to where We to have formulations advanced preparing are provide investigation. healthcare preclinical point ViiV the
We are a process working also the a with in of variety Genentech projects few just examples. to provide on of
this could hope relationships these that early be from available is Our data later year.
Furthermore, compounds. and Infectious NIH Disease efficacy with now been discussions therapeutic platform apply have treatment LNC intensified opportunities identify options that our Institute have proprietary injectable for to the at of Covid-XX, our the these or others for Allergy IV there National and of as demonstrations we to the of
would therapies be viable confronting oral Covid-XX. tolerated patients and goal formulate Our well to for
potentially role all While of materialize become active playing to urgency there providing sense available. a on look ongoing, are as discussions is forward very a sides. appropriate obviously updates they and and And we these
and same our $X.X the previous to approximately million $X.XX of company results, shareholders first compared reported XXXX basic million year. attributable to or net share of quarter of $X.X to for approximately the basic or a for common diluted diluted the share to the $X.XX the now net loss attributable loss financial and per shareholders Turning a common quarter
of first million expenses development due Research $X.X the costs. expenses the in year's to was quarter million The General development previous approximately XXXX $X.X MATXXXX clinical first $X.X to of primarily to expenses to approximately increase compared due million. million were The the quarter of related increase higher expenses G&A quarter same compensation primarily approximately development and and the $X.X quarter was and administrative first approximately compared MATXXXX. of the higher in year. to were employee in XXXX last
into at million ended balance equivalents $XX.X compared year-end approximately $XX.X fund proceeds from our we to of operations the current Based on million of million securities approximately completed includes Turning quarter the projections public XXXX in to and sufficient This company's to cash the approximately believe we hand is that half increase on offering XXXX. with first marketable net cash January. first of $XX.X of cash, XXXX. sheet,
advance during full and significant inflection extends as well potentially extremely almost A for inflection that security beyond three many toward uncertainty points of is significant runway an companies. our important these cash points. otherwise provides products This we years great period
that be and extremely are drive opportunistic conclude able the we to in important financing We first an and the pleased strategy. were company our to business quarter protect
confident in overall committed summary, and and need. developing am a in am to uncertain overarching as thank them circumstances at through I reaching proud are we out and and business we beginning commend the dedication continue progress this have adapt from And I of tremendous for these In made we of we continuity times. for critical position therapies goal of the our milestones times. uncertain teammates standpoint that I the achieving strong to laid to areas their all work the of evolve. together a We remain will year these get my important drive for as we continued
remain lies ahead operator call With remainder about excited of and prepared all I that our beyond. the question-and-answer We the for our remarks the we turn session. conclusion very have for company to the of and will reached what over the XXXX for
